Regeneron and Sanofi: An Unstoppable Biotech Duo?

This morning, positive results from a phase 2a study testing an experimental asthma drug developed by biotech Regeneron (NASDAQ: REGN  )  and big pharma company Sanofi (NYSE: SNY  ) were published in the New England Journal of Medicine. In the following video, health-care analyst Max Macaluso discusses the details of the trial and offers his long-term view on both stocks.

While investors have made huge gains with Regeneron in the past 12 months, this is one of many biotech stocks that does not pay a dividend. If you're on the lookout for high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2445477, ~/Articles/ArticleHandler.aspx, 7/29/2014 3:03:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement